Individualized Care for Prostate Cancer

Active surveillance of low- and mid-risk prostate cancer is becoming a widely accepted alternative to quickly administering more aggressive forms of therapy upon diagnosis. Educating patients on the finer details of their battles with prostate cancer and involving them in the treatment decision-making process is “the wave of the future.”

As diagnostic technology continues to improve, especially in the oncology space, physicians are gaining access to tools that help them and their patients better manage long-term treatment plans. One of these advanced diagnostic tools is Prolaris, a genetic test that gathers patient-specific information about the severity of each individual instance of prostate cancer and estimates the patient’s risk of dying within 10 years.